Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go:
Extended
investment:
£10,000
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Payment fraud and identity verification are real threats to businesses and customers, but Fingopay has developed a solution. A highly secure biometric reader that scans a person's unique finger vein to complete transactions in seconds. Customer details are stored in the cloud and can be used to offer promotions and deals. Successful pilots have been achieved in Brunel University, Copenhagen Business School and Proud Bar in Camden. Fingopay has partnerships with VISA, Worldpay and Nets.
days to go:
Expired
investment:
£1,216,240
Argento Labs, a UK-based biotech company, is dedicated to converting waste into valuable resources, leading the way in sustainable innovation. They utilize patented bioprocessing technology to extract sugars, proteins, and fats from agricultural, forestry, and municipal waste. Their product range includes alternative proteins, biogenic CO2, and bio-fertilizers, contributing to environmental sustainability and decarbonization efforts. Argento Labs focuses on scalability for industrial production to support a sustainable future and envisions waste as a transformative solution for preserving the planet. Their patent currently applies in the US jurisdiction.
days to go:
Expired
investment:
£415,233
Chip is one of the fastest-growing Fintech companies in the UK. Chip has built an app that uses the user's banking app to make personalised decisions about their money. Its user base has doubled since its previous fundraising in 2018. The company has 153,000 accounts, and it has processed more than £130m of savings. ChipX is the company's revolutionary returns platform and it has a waiting list of more than 50,000 people. The company is a winner of the British Bank Award, 2 Crowdcube awards, and 1 World Banking Award. It has welcomed many management executives from Funding Circle, Monzo, and Purple Bricks. Chip is now scaling with market-leading returns on ChipX. It aims to build the biggest savings account in the world. With the proceeds, the company will double its team and expand ChipX in the €10 trillion European savings market.
days to go:
Expired
investment:
£3,768,260
JustUs plans to offer its own ISA's directly to consumers via IFA's and by doing so they are disrupting the £1.5 trillion lending and savings market in the UK.
days to go:
Expired
investment:
£12,580
